{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:04:35Z","timestamp":1791583475284,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.survophthal.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:28:48Z","timestamp":1756308528000},"page":"207-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Placebo or vehicle effects on dry eye signs and symptoms in randomized controlled trials: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7236-5254","authenticated-orcid":false,"given":"Alan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-1355","authenticated-orcid":false,"given":"Gui-shuang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.survophthal.2025.08.014_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","article-title":"Meta-Regression analysis of placebo response in antipsychotic trials, 1970\u20132010","volume":"170","author":"Agid","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtos.2013.02.002","article-title":"Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies","volume":"11","author":"Alves","year":"2013","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5301\/ejo.5000229","article-title":"Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sj\u00f6gren syndrome","volume":"23","author":"Aragona","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"14","key":"10.1016\/j.survophthal.2025.08.014_bib4","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2025.08.014_bib5","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3109\/02713683.2015.1122810","article-title":"A randomized controlled trial of omega 3 fatty acids in rosacea patients with dry eye symptoms","volume":"41","author":"Bhargava","year":"2016","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/ICO.0000000000000386","article-title":"Oral Omega-3 fatty acid treatment for dry eye in contact lens wearers","volume":"34","author":"Bhargava","year":"2015","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/ICL.0000000000000179","article-title":"Short-Term omega 3 fatty acids treatment for dry eye in young and Middle-Aged visual display terminal users","volume":"42","author":"Bhargava","year":"2016","journal-title":"Eye Contact Lens Sci Clin Pr"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clae.2015.01.007","article-title":"Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye","volume":"38","author":"Bhargava","year":"2015","journal-title":"Contact Lens Anterior Eye"},{"issue":"7","key":"10.1016\/j.survophthal.2025.08.014_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/j.1532-2149.2011.00104.x","article-title":"Sex differences in analgesic response to ibuprofen are influenced by expectancy: a randomized, crossover, balanced placebo-designed study","volume":"16","author":"Butcher","year":"2012","journal-title":"Eur J Pain"},{"issue":"12","key":"10.1016\/j.survophthal.2025.08.014_bib10","doi-asserted-by":"crossref","DOI":"10.1615\/IntJMedMushrooms.2022045307","article-title":"Efficacy of cordyceps cicadae (Ascomycota) mycelium supplementation for amelioration of dry eye symptoms: a randomized, Double-Blind clinical pilot study","volume":"24","author":"Chang","year":"2022","journal-title":"Int J Med Mushrooms"},{"key":"10.1016\/j.survophthal.2025.08.014_bib11","article-title":"The repeatability of tests for dry eye signs and symptoms in the dry eye assessment and management (DREAM) study","author":"Chen","year":"2024","journal-title":"Contact Lens Anterior Eye"},{"issue":"31","key":"10.1016\/j.survophthal.2025.08.014_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.survophthal.2025.08.014_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139761","article-title":"Clinical effect of antioxidant glasses containing extracts of medicinal plants in patients with dry eye disease: a Multi-Center, prospective, randomized, Double-Blind, Placebo-Controlled trial","volume":"10","author":"Choi","year":"2015","journal-title":"PLOS ONE"},{"issue":"10","key":"10.1016\/j.survophthal.2025.08.014_bib14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bjo.83.10.1121","article-title":"Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w\/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome","volume":"83","author":"Condon","year":"1999","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ophtha.2016.09.023","article-title":"A randomized, Double-Masked, Placebo-Controlled clinical trial of two forms of Omega-3 supplements for treating dry eye disease","volume":"124","author":"Deinema","year":"2017","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2025.08.014_bib16","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10792-022-02245-1","article-title":"TNF-\u03b1 inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China","volume":"42","author":"Dong","year":"2022","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.08.014_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jtos.2013.11.002","article-title":"Fluorescein-Tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: a systematic review and Meta-Analysis","volume":"12","author":"Doughty","year":"2014","journal-title":"Ocul Surf"},{"issue":"12__4","key":"10.1016\/j.survophthal.2025.08.014_bib18","first-page":"S7","article-title":"Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain","volume":"65","author":"Dworkin","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in Medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.survophthal.2025.08.014_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00160","article-title":"Does Sex\/Gender play a role in placebo and nocebo effects? Conflicting evidence from clinical trials and experimental studies","volume":"13","author":"Enck","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.survophthal.2025.08.014_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12886-023-03004-1","article-title":"Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial","volume":"23","author":"Eom","year":"2023","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.08.014_bib22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/ICO.0000000000000940","article-title":"Effect of oral Re-esterified Omega-3 nutritional supplementation on dry eyes","volume":"35","author":"Epitropoulos","year":"2016","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000096490","article-title":"Immediate placebo effect in Parkinson\u2019s disease \u2013 is the subjective relief accompanied by objective improvement?","volume":"56","author":"Fregni","year":"2006","journal-title":"Eur Neurol"},{"key":"10.1016\/j.survophthal.2025.08.014_bib24","unstructured":"Golden M.I., Meyer J.J., Zeppieri M., Patel B.C. Dry Eye Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Dec 9]. Available from: \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470411\/\u3009."},{"issue":"12","key":"10.1016\/j.survophthal.2025.08.014_bib25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/ICO.0000000000000627","article-title":"Dry eye signs and symptoms persist during systemic neutralization of IL-1\u03b2 by canakinumab or IL-17A by secukinumab","volume":"34","author":"Grosskreutz","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2025.08.014_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100730","article-title":"Shuang. Magnitude and predictors of the placebo effects in the dry eye assessment and management (DREAM) study","volume":"5","author":"Han","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.survophthal.2025.08.014_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2014.01079","article-title":"Prediction of placebo responses: a systematic review of the literature","volume":"5","author":"Horing","year":"2014","journal-title":"Front Psychol"},{"issue":"21","key":"10.1016\/j.survophthal.2025.08.014_bib28","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","article-title":"Is the placebo powerless?","volume":"344","author":"Hr\u00f3bjartsson","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169069","article-title":"Clinical evaluation of a royal jelly supplementation for the restoration of dry eye: a prospective randomized double blind placebo controlled study and an experimental mouse model","volume":"12","author":"Inoue","year":"2017","journal-title":"PLOS ONE"},{"issue":"11","key":"10.1016\/j.survophthal.2025.08.014_bib30","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ophtha.2013.04.006","article-title":"Short-term consumption of oral Omega-3 and dry eye syndrome","volume":"120","author":"Kangari","year":"2013","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2025.08.014_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234186","article-title":"Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: a double-masked, randomized trial","volume":"15","author":"Kasetsuwan","year":"2020","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.survophthal.2025.08.014_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtos.2015.12.005","article-title":"Dietary supplementation with a combination of lactoferrin, fish oil, and enterococcus faecium WB2000 for treating dry eye: a rat model and human clinical study","volume":"14","author":"Kawashima","year":"2016","journal-title":"Ocul Surf"},{"issue":"8","key":"10.1016\/j.survophthal.2025.08.014_bib33","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3945\/jn.109.118901","article-title":"Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry Eye1,2,3,4","volume":"140","author":"Larmo","year":"2010","journal-title":"J Nutr"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib34","article-title":"Perioperative intense pulsed light to prevent and improve symptoms of post-laser corneal refractive surgery dry eye. A randomized clinical trial","volume":"13","author":"Mart\u00ednez-Hergueta","year":"2024","journal-title":"AsiaPac J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.08.014_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jamaophthalmol.2022.4394","article-title":"Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States","volume":"140","author":"McCann","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/sim.4780020401","article-title":"How much of the placebo \u2018effect\u2019 is really statistical regression?","volume":"2","author":"McDonald","year":"1983","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.survophthal.2025.08.014_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.optom.2020.10.002","article-title":"Why the symptoms and objective signs of dry eye disease May not correlate","volume":"14","author":"McMonnies","year":"2021","journal-title":"J Optom"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jclinepi.2005.12.001","article-title":"The nature and power of the placebo effect","volume":"59","author":"Miller","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib42","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s40123-023-00720-1","article-title":"Possible strategies to mitigate placebo or vehicle response in dry eye disease trials: a narrative review","volume":"12","author":"Montecchi-Palmer","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/OPX.0000000000001826","article-title":"Effect of a novel Omega-3 and Omega-6 fatty acid supplement on dry eye disease: a 3-month randomized controlled trial","volume":"99","author":"Ng","year":"2022","journal-title":"Optom Vis Sci"},{"issue":"15","key":"10.1016\/j.survophthal.2025.08.014_bib44","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.3390\/nu14153236","article-title":"An oral polyphenol formulation to modulate the ocular surface inflammatory process and to improve the symptomatology associated with dry eye disease","volume":"14","author":"Ng","year":"2022","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.survophthal.2025.08.014_bib45","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.survophthal.2025.08.014_bib46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/j.pain.0000000000002038","article-title":"Effects of sex on placebo effects in chronic pain participants: a cross-sectional study","volume":"162","author":"Olson","year":"2021","journal-title":"PAIN"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sj\u00f6gren\u2019s syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.08.014_bib48","series-title":"Natural Products and Human Diseases: Pharmacology, Molecular Targets, and Therapeutic Benefits [Internet]","first-page":"377","article-title":"Safety and efficacy of oral supplementation of lentil (Lens culinaris Medic) in dry eye patients","author":"Panahi","year":"2021"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib49","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1038\/s41598-022-07427-6","article-title":"Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial","volume":"12","author":"Park","year":"2022","journal-title":"Sci Rep"},{"issue":"null","key":"10.1016\/j.survophthal.2025.08.014_bib50","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2147\/OPTH.S95242","article-title":"Tear film osmolarity and dry eye disease: a review of the literature","volume":"9","author":"Potvin","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.08.014_bib51","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11096-022-01439-y","article-title":"Placebo administration for dry eye disease: a level I evidence based systematic review and meta-analysis","volume":"44","author":"Prinz","year":"2022","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.survophthal.2025.08.014_bib52","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/cxo.12910","article-title":"Effects of intranasal administration of violet oil in dry eye disease","volume":"102","author":"Saffar Shahroodi","year":"2019","journal-title":"Clin Exp Optom"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib53","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s12325-021-01680-3","article-title":"A phase II, multicenter, randomized, Placebo-Controlled, Double-Masked trial of a topical estradiol ophthalmic formulation in postmenopausal women with Moderate-to-Severe dry eye disease","volume":"38","author":"Schmidl","year":"2021","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.survophthal.2025.08.014_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcjo.2012.08.019","article-title":"Effects of phytoestrogen supplementation in postmenopausal women with dry eye syndrome: a randomized clinical trial","volume":"47","author":"Scuderi","year":"2012","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.08.014_bib55","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1111\/aos.13140","article-title":"Paralysis of the orbicularis muscle of the eye using botulinum toxin type a in the treatment for dry eye","volume":"95","author":"Serna-Ojeda","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.08.014_bib56","article-title":"The neglect of sex: a call to action for including sex as a biological variable in placebo and nocebo research","volume":"116","author":"Shafir","year":"2022","journal-title":"Conte Clin Trials"},{"issue":"8","key":"10.1016\/j.survophthal.2025.08.014_bib57","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/j.1755-3768.2010.02027.x","article-title":"Acupuncture for treating dry eye: a randomized placebo-controlled trial","volume":"88","author":"Shin","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib58","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4103\/0301-4738.278367","article-title":"Effects of preoperative doses of betamethasone acetate 0.1% on dry eye control after cataract surgery","volume":"68","author":"Shokoohi-Rad","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.08.014_bib59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2013.10.002","article-title":"Challenges in using signs and symptoms to evaluate new biomarkers of dry eye disease","volume":"12","author":"Sullivan","year":"2014","journal-title":"Ocul Surf"},{"issue":"9","key":"10.1016\/j.survophthal.2025.08.014_bib60","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/ICO.0b013e318242fd60","article-title":"Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management","volume":"31","author":"Sullivan","year":"2012","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.survophthal.2025.08.014_bib61","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-Masked, Placebo-Controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.survophthal.2025.08.014_bib62","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.08.014_bib63","doi-asserted-by":"crossref","unstructured":"The Dry Eye Assessment and Management Study Research Group. n\u22123 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 3;378(18):1681\u20131690. doi:10.1056\/NEJMoa17096912018 May 3.","DOI":"10.1056\/NEJMoa1709691"},{"issue":"12","key":"10.1016\/j.survophthal.2025.08.014_bib64","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/ICL.0000000000001026","article-title":"Update on dry eye disease treatment: evidence from randomized controlled trials","volume":"49","author":"Ucakhan","year":"2023","journal-title":"Eye Contact Lens"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib65","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ajo.2009.09.023","article-title":"Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (Vismed, Rejena)","volume":"149","author":"Vogel","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.08.014_bib66","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jclinepi.2006.11.003","article-title":"Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews","volume":"60","author":"Walter","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.survophthal.2025.08.014_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jtos.2024.07.004","article-title":"Discriminative performance of ocular surface staining and lid wiper epitheliopathy in dry eye disease: an investigator-masked, prospective registry-based, diagnostic accuracy study","volume":"34","author":"Wang","year":"2024","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.survophthal.2025.08.014_bib68","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/ICO.0b013e3181d82f5e","article-title":"Clinical trials of therapeutic ocular surface medium for moderate to severe dry eye","volume":"29","author":"Watson","year":"2010","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.survophthal.2025.08.014_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000365248","article-title":"Age and sex as moderators of the placebo response - an evaluation of systematic reviews and Meta-Analyses across Medicine","volume":"61","author":"Weimer","year":"2014","journal-title":"Gerontology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S2215-0366(14)00092-3","article-title":"Placebo effects in psychiatry: mediators and moderators","volume":"2","author":"Weimer","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICO.0b013e3181f22e03","article-title":"Pilot, prospective, randomized, Double-masked, Placebo-controlled clinical trial of an Omega-3 supplement for dry eye","volume":"30","author":"Wojtowicz","year":"2011","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.survophthal.2025.08.014_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"issue":"7","key":"10.1016\/j.survophthal.2025.08.014_bib73","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","article-title":"Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren\u2019s syndrome: a Double-Blind randomized control study","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.08.014_bib74","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu","year":"2011","journal-title":"Cornea"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:28:14Z","timestamp":1778945294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0039625725001468"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.08.014","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo or vehicle effects on dry eye signs and symptoms in randomized controlled trials: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}